Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort.

Ferriero M, Mastroianni R, De Nunzio C, Cindolo L, Calabrò F, Tema G, Leonardo C, Flammia RS, Tuderti G, Anceschi U, Brassetti A, Giacinti S, Guaglianone S, Ghahhari J, Schips L, Tubaro A, Gallucci M, Simone G.

World J Urol. 2019 Oct 12. doi: 10.1007/s00345-019-02974-6. [Epub ahead of print]

PMID:
31605196
2.

Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.

Miyake H, Sugiyama T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Otsuka A.

Clin Genitourin Cancer. 2018 Jun;16(3):219-225. doi: 10.1016/j.clgc.2017.11.007. Epub 2017 Dec 6.

PMID:
29274813
3.

Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.

Matsubara N, Yamada Y, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S, Otsuka M, Fukasawa S.

Clin Genitourin Cancer. 2018 Apr;16(2):142-148. doi: 10.1016/j.clgc.2017.09.008. Epub 2017 Sep 23.

PMID:
29042308
4.

Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.

Fan L, Wang R, Chi C, Cai W, Zhang Y, Qian H, Shao X, Wang Y, Xu F, Pan J, Zhu Y, Shangguan X, Zhou L, Dong B, Xue W.

Prostate. 2018 Mar;78(4):250-256. doi: 10.1002/pros.23465. Epub 2017 Dec 29.

PMID:
29285775
5.

Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.

Yamada Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S.

BMC Res Notes. 2016 Oct 18;9(1):471.

6.

Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.

Poon DM, Chan K, Lee SH, Chan TW, Sze H, Lee EK, Lam D, Chan MF.

BMC Urol. 2016 Mar 22;16:12. doi: 10.1186/s12894-016-0132-z.

7.

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.

Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES.

Prostate. 2014 Sep;74(13):1278-85. doi: 10.1002/pros.22844. Epub 2014 Jul 22.

8.

Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.

Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M.

Clin Genitourin Cancer. 2017 Aug;15(4):e591-e597. doi: 10.1016/j.clgc.2016.12.015. Epub 2016 Dec 22.

PMID:
28063845
9.

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.

10.

The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy.

Zhao J, Shen P, Sun G, Chen N, Liu J, Tang X, Huang R, Cai D, Gong J, Zhang X, Chen Z, Li X, Wei Q, Zhang P, Liu Z, Liu J, Zeng H.

Oncotarget. 2017 Jul 24;8(33):55374-55383. doi: 10.18632/oncotarget.19520. eCollection 2017 Aug 15.

11.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.

Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.

PMID:
29074061
12.

Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.

Chang LW, Hung SC, Wang SS, Li JR, Yang CK, Chen CS, Ho HC, Cheng CL, Ou YC, Chiu KY.

Anticancer Res. 2019 Jul;39(7):3901-3908. doi: 10.21873/anticanres.13541.

PMID:
31262919
13.

Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer.

Salem S, Komisarenko M, Timilshina N, Martin L, Grewal R, Alibhai S, Finelli A.

Clin Oncol (R Coll Radiol). 2017 Sep;29(9):601-608. doi: 10.1016/j.clon.2017.03.010. Epub 2017 Apr 8.

PMID:
28395931
14.
15.

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.

Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J.

Eur Urol. 2018 Aug;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035. Epub 2018 Feb 10.

16.

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.

Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM.

Eur Urol. 2017 Nov;72(5):828-834. doi: 10.1016/j.eururo.2017.07.024. Epub 2017 Aug 14.

PMID:
28818355
17.

Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.

Emamekhoo H, Barata PC, Edwin NC, Woo KM, Grivas P, Garcia JA.

Clin Genitourin Cancer. 2018 Dec;16(6):429-436. doi: 10.1016/j.clgc.2018.08.002. Epub 2018 Aug 17.

PMID:
30236961
18.

Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ.

Eur Urol. 2017 Jul;72(1):10-13. doi: 10.1016/j.eururo.2017.03.007. Epub 2017 Mar 15.

PMID:
28314611
19.

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study.

Cindolo L, Natoli C, De Nunzio C, De Tursi M, Valeriani M, Giacinti S, Micali S, Rizzo M, Bianchi G, Martorana E, Scarcia M, Ludovico GM, Bove P, Laudisi A, Selvaggio O, Carrieri G, Bada M, Castellan P, Boccasile S, Ditonno P, Chiodini P, Verze P, Mirone V, Schips L.

BMC Cancer. 2017 Nov 10;17(1):753. doi: 10.1186/s12885-017-3755-x.

20.

Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone.

Fan L, Wang X, Chi C, Wang Y, Cai W, Shao X, Xu F, Pan J, Zhu Y, Shangguan X, Xin Z, Hu J, Xie S, Wang R, Zhou L, Dong B, Xue W.

Prostate. 2017 Sep;77(12):1233-1241. doi: 10.1002/pros.23381. Epub 2017 Jul 28.

PMID:
28752926

Supplemental Content

Support Center